Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

NYSE - LSE

BCE	0.87%	23.605	$
NGG	-0.5%	77.66	$
JRI	0.9%	12.19	$
RYCEF	-0.15%	19.56	$
RELX	4.48%	36.8	$
BCC	2.17%	78	$
RBGPF	-3.2%	70	$
GSK	0.14%	50.51	$
CMSC	0.12%	21.055	$
AZN	1.4%	163.92	$
RIO	0.07%	102.82	$
BP	-0.02%	43.92	$
VOD	3.34%	16.625	$
BTI	1.15%	56.325	$
CMSD	-0.12%	20.765	$

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

BOULEVARD 17.03.2025

DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2025 were approximately $2.5 million, an increase of approximately $0.1 million when compared to the same period last year. Net income for the quarter ended January 31, 2025 was almost breakeven, representing an earnings increase of approximately $0.3 million when compared to the same period last year.

Text size:

"As reflected in this quarter's results, we began experiencing net revenue growth in the markets we serve. With projects underway in Europe, Asia, and Latin America, we are poised for continued expansion as we drive growth by anticipating client needs and delivering unmatched solutions," stated Mr. Sanchez, Chief Executive Officer of the Company.

About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv Inc.

View the original press release on ACCESS Newswire

M.King--AT

Arizona Tribune - Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025

Featured

US feminist icon Gloria Steinem dies at 92: foundation

Vast aid challenge after 'Himalayan tsunami' devastates Nepal

Grief on Chinese internet as wait for Tibet flood news drags on

Caruana Galizia: 'one-woman WikiLeaks' who exposed Malta's shady side